Targeting Microvascular Circulation

About Diamedica Therapeutics

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with the focus on neurological and kidney diseases.

About DiaMedica Therapeutics ›

Research & Development

DiaMedica Therapeutics’ lead clinical stage product, DM199, is a recombinant human tissue kallikrien (rhKLK-1) protein to treat acute ischemic stroke and kidney disease.

About R&D ›